Katherine S. Ralston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katherine S. Ralston has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Kent L. Hill
Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA
8 shared publications Hannah W. Miller
Department of Microbiology and Molecular Genetics, University of California, Davis, Davis, California, USA
6 shared publicationsWesley Huang
Department of Microbiology and Molecular Genetics, University of California, Davis, USA
6 shared publications- Maura C. Ruyechan
Department of Microbiology and Molecular Genetics, University of California, Davis, CA, USA
4 shared publications Rene L. Suleiman
Department of Microbiology and Molecular Genetics, University of California, Davis, USA
4 shared publications- William A. Petri
Division of Infectious Diseases and International Health, University of Virginia School of Medicine
4 shared publications
Latest Publications
- 22 June 2026
- Published by Elsevier in Current Biology
- Vol. 36 (12) , R683-R685
Trogocytosis
- Open Access
CRISPR/Cas9 knockout and editing of the major cysteine protease in Entamoeba histolytica
Entamoeba histolytica is the cause of amoebiasis, a diarrheal infection that is a significant source of morbidity and mortality. Despite its importance to human health, the basic mechanism of disease is poorly understood. E. histolytica is dramatically understudied, even in comparison to other understudied parasites, due to challenging features of its genome and the relative paucity of genetic tools. A major limitation is the historical lack of gene knockouts or manipulation of the endogenous genome. While CRISPR/Cas9 has led to major advances in the tractability of numerous parasites, until recently, it was not applied in E. histolytica, except for the demonstration of editing of an episomal plasmid. In this study, we further developed CRISPR/Cas9 and demonstrated the successful targeting of the endogenous cysteine protease 5 (CP5) gene, a major virulence factor. Further, we demonstrated successful CRISPR/Cas9-based editing of this locus, which represents the very first successful editing of the endogenous genome. In the course of these approaches, we developed the viral skip peptide approach as well as a suite of endogenous promoters to drive tunable levels of gene expression. We also performed the most extensive empirical testing of nuclear localization signals in E. histolytica that has been done. Thus, this work demonstrates effective CRISPR/Cas9-based manipulation of the endogenous genome, together with significant advances to the overall genetic toolkit that extend beyond CRISPR/Cas9. These great improvements in the tractability of E. histolytica thus set the stage for future studies to better define its virulence.
Open AccessCRISPR/Cas9 knockout and editing of the major cysteine protease in Entamoeba histolytica
Entamoeba histolytica is the cause of amoebiasis, a diarrheal infection that is a significant source of morbidity and mortality. Despite its importance to human health, the basic mechanism of disease is poorly understood. E. histolytica is dramatically understudied, even in comparison to other understudied parasites, due to challenging features of its genome and the relative paucity of genetic tools. A major limitation is the historical lack of gene knockouts or manipulation of the endogenous genome. While CRISPR/Cas9 has led to major advances in the tractability of numerous parasites, until recently, it was not applied in E. histolytica, except for the demonstration of editing of an episomal plasmid. In this study, we further developed CRISPR/Cas9 and demonstrated the successful targeting of the endogenous cysteine protease 5 (CP5) gene, a major virulence factor. Further, we demonstrated successful CRISPR/Cas9-based editing of this locus, which represents the very first successful editing of the endogenous genome. In the course of these approaches, we developed the viral skip peptide approach as well as a suite of endogenous promoters to drive tunable levels of gene expression. We also performed the most extensive empirical testing of nuclear localization signals in E. histolytica that has been done. Thus, this work demonstrates effective CRISPR/Cas9-based manipulation of the endogenous genome, together with significant advances to the overall genetic toolkit that extend beyond CRISPR/Cas9. These great improvements in the tractability of E. histolytica thus set the stage for future studies to better define its virulence.
- Open Access
Human cell cytoskeletal rigidity differentially influences trogocytosis and phagocytosis by Entamoeba histolytica
Entamoeba histolytica is a parasitic amoeba and the cause of amoebiasis, a common but understudied human diarrheal disease. E. histolytica trophozoites ("amoebae") kill human cells through a process of cell-nibbling called trogocytosis (trogo-: nibble) that contributes to tissue damage. Amoebae can also perform phagocytosis, in which entire human cells are ingested. Based on studies in which human cells were artificially stiffened, it was suggested that amoebae perform phagocytosis on stiffer cells, and trogocytosis on less stiff cells. A few recent studies of macrophage ingestion of artificial targets or artificially stiffened target cells also suggested a similar relationship between target stiffness and trogocytosis/phagocytosis efficiencies. To better evaluate the impact of target cell stiffness on amoebic ingestion, instead of using artificial targets or artificial cell stiffening, we created human cell mutants in which individual genes were knocked down. We targeted seven different genes in the Rho-pathway, which have well-characterized roles in regulating actomyosin dynamics. Strikingly, amoebae performed quantitatively reduced levels of trogocytosis on all knockdown mutants, including relatively stiffer mutants and relatively less stiff mutants. In contrast, amoebic phagocytosis efficiency was inversely correlated with human cell stiffness. Thus, human cell stiffness differentially influences amoebic trogocytosis and phagocytosis. This is more complex than the conclusions of studies that used artificial targets or artificially stiffened cells. Our results emphasize that the dynamic nature of the cytoskeleton in living cells impacts trogocytosis. In addition to shedding light on the burgeoning field of eukaryotic trogocytosis, this work extends knowledge of amoebic ingestion processes that contribute to disease.
Open AccessHuman cell cytoskeletal rigidity differentially influences trogocytosis and phagocytosis by Entamoeba histolytica
Entamoeba histolytica is a parasitic amoeba and the cause of amoebiasis, a common but understudied human diarrheal disease. E. histolytica trophozoites ("amoebae") kill human cells through a process of cell-nibbling called trogocytosis (trogo-: nibble) that contributes to tissue damage. Amoebae can also perform phagocytosis, in which entire human cells are ingested. Based on studies in which human cells were artificially stiffened, it was suggested that amoebae perform phagocytosis on stiffer cells, and trogocytosis on less stiff cells. A few recent studies of macrophage ingestion of artificial targets or artificially stiffened target cells also suggested a similar relationship between target stiffness and trogocytosis/phagocytosis efficiencies. To better evaluate the impact of target cell stiffness on amoebic ingestion, instead of using artificial targets or artificial cell stiffening, we created human cell mutants in which individual genes were knocked down. We targeted seven different genes in the Rho-pathway, which have well-characterized roles in regulating actomyosin dynamics. Strikingly, amoebae performed quantitatively reduced levels of trogocytosis on all knockdown mutants, including relatively stiffer mutants and relatively less stiff mutants. In contrast, amoebic phagocytosis efficiency was inversely correlated with human cell stiffness. Thus, human cell stiffness differentially influences amoebic trogocytosis and phagocytosis. This is more complex than the conclusions of studies that used artificial targets or artificially stiffened cells. Our results emphasize that the dynamic nature of the cytoskeleton in living cells impacts trogocytosis. In addition to shedding light on the burgeoning field of eukaryotic trogocytosis, this work extends knowledge of amoebic ingestion processes that contribute to disease.
- Open Access
- 31 July 2025
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 93 (9) , e0022025
Cross-species protection suggests Entamoeba histolytica trogocytosis enables complement resistance through the transfer of negative regulators of complement activation
Entamoeba histolytica is a major cause of diarrheal disease. E. histolytica trophozoites (“amoebae”) can invade the intestine and disseminate via the bloodstream, resisting complement lysis through unknown mechanisms. Amoebae kill human cells by performing trogocytosis. After performing trogocytosis, amoebae display human proteins on their own surface and are resistant to lysis by human serum. In this study, we sought to further evaluate the mechanism by which amoebae resist complement lysis. To test if complement is responsible for lysis of amoebae, C3-depleted serum was compared to replete serum, and C3 was indeed required for lysis. Amoebae were allowed to perform trogocytosis of human cells and exposed to mouse serum. Although they had performed trogocytosis on a different species than the source of the serum, they were protected from lysis. To test if the protection from lysis by mouse serum was due to the functional interchangeability of human and mouse complement pathway proteins, human CD46 or CD55 (negative regulators of complement activation) were exogenously expressed. Amoebae that expressed human CD46 or CD55 were protected from lysis by mouse serum, indicating that display of human proteins was sufficient to inhibit mouse complement activation. Finally, amoebae were allowed to perform trogocytosis of a cell type in which the complement pathway is not conserved, and they did not become resistant to lysis. Overall, these findings are consistent with the model that trogocytosis enables amoebic acquisition and display of host proteins, including negative regulators of the complement pathway, that provide protection from complement lysis. Since other microbes can perform trogocytosis, this novel mechanism for complement resistance might apply to other infections.
- 31 July 2025
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 93 (9) , e0022025
Open AccessCross-species protection suggests Entamoeba histolytica trogocytosis enables complement resistance through the transfer of negative regulators of complement activation
Entamoeba histolytica is a major cause of diarrheal disease. E. histolytica trophozoites (“amoebae”) can invade the intestine and disseminate via the bloodstream, resisting complement lysis through unknown mechanisms. Amoebae kill human cells by performing trogocytosis. After performing trogocytosis, amoebae display human proteins on their own surface and are resistant to lysis by human serum. In this study, we sought to further evaluate the mechanism by which amoebae resist complement lysis. To test if complement is responsible for lysis of amoebae, C3-depleted serum was compared to replete serum, and C3 was indeed required for lysis. Amoebae were allowed to perform trogocytosis of human cells and exposed to mouse serum. Although they had performed trogocytosis on a different species than the source of the serum, they were protected from lysis. To test if the protection from lysis by mouse serum was due to the functional interchangeability of human and mouse complement pathway proteins, human CD46 or CD55 (negative regulators of complement activation) were exogenously expressed. Amoebae that expressed human CD46 or CD55 were protected from lysis by mouse serum, indicating that display of human proteins was sufficient to inhibit mouse complement activation. Finally, amoebae were allowed to perform trogocytosis of a cell type in which the complement pathway is not conserved, and they did not become resistant to lysis. Overall, these findings are consistent with the model that trogocytosis enables amoebic acquisition and display of host proteins, including negative regulators of the complement pathway, that provide protection from complement lysis. Since other microbes can perform trogocytosis, this novel mechanism for complement resistance might apply to other infections.
- 18 April 2025
- Published by Elsevier in Trends in Parasitology
- Vol. 41 (5) , 401-415
Work with me here: variations in genome content and emerging genetic tools in Entamoeba histolytica
- 18 April 2025
- Published by Elsevier in Trends in Parasitology
- Vol. 41 (5) , 401-415
Work with me here: variations in genome content and emerging genetic tools in Entamoeba histolytica
- 14 October 2024
- Published by Elsevier in Trends in Parasitology
- Vol. 40 (11) , 935-941
ICAP 2024: anaerobic protozoology in focus, a partnership with parasitology societies in the South Pacific
- 14 October 2024
- Published by Elsevier in Trends in Parasitology
- Vol. 40 (11) , 935-941
ICAP 2024: anaerobic protozoology in focus, a partnership with parasitology societies in the South Pacific
- Open Access
Cross-species protection suggests Entamoeba histolytica trogocytosis enables complement resistance through the transfer of negative regulators of complement activation
Entamoeba histolytica is a major cause of diarrheal disease. E. histolytica trophozoites (“amoebae”) can invade the intestine and disseminate via the bloodstream, resisting complement lysis through unknown mechanisms. Amoebae kill human cells by performing trogocytosis. After performing trogocytosis, amoebae display human proteins on their own surface and are resistant to lysis by human serum. In this study we sought to further evaluate the mechanism by which amoebae resist complement. To test if complement is responsible for lysis of amoebae, C3-depleted serum was compared to replete serum, and C3 was required for lysis. Amoebae were allowed to perform trogocytosis of human cells and exposed to mouse serum. Although they had performed trogocytosis on a different species than the source of the serum, they were protected from lysis. To test if the protection from lysis by mouse serum was due to the functional interchangeability of human and mouse complement pathway proteins, human CD46 or CD55 (negative regulators of complement activation) were exogenously expressed. Amoebae that expressed human CD46 or CD55 were protected from lysis by mouse serum, indicating that display of human proteins was sufficient to inhibit mouse complement activation. Finally, amoebae were allowed to perform trogocytosis of a cell type in which the complement pathway is not conserved, and they did not become resistant to lysis. Overall, these findings are consistent with the model that trogocytosis enables amoebic acquisition and display of host proteins, including negative regulators of the complement pathway, that provide protection from complement lysis. Since other microbes can perform trogocytosis, this novel mechanism for complement resistance might apply to other infections.
Open AccessCross-species protection suggests Entamoeba histolytica trogocytosis enables complement resistance through the transfer of negative regulators of complement activation
Entamoeba histolytica is a major cause of diarrheal disease. E. histolytica trophozoites (“amoebae”) can invade the intestine and disseminate via the bloodstream, resisting complement lysis through unknown mechanisms. Amoebae kill human cells by performing trogocytosis. After performing trogocytosis, amoebae display human proteins on their own surface and are resistant to lysis by human serum. In this study we sought to further evaluate the mechanism by which amoebae resist complement. To test if complement is responsible for lysis of amoebae, C3-depleted serum was compared to replete serum, and C3 was required for lysis. Amoebae were allowed to perform trogocytosis of human cells and exposed to mouse serum. Although they had performed trogocytosis on a different species than the source of the serum, they were protected from lysis. To test if the protection from lysis by mouse serum was due to the functional interchangeability of human and mouse complement pathway proteins, human CD46 or CD55 (negative regulators of complement activation) were exogenously expressed. Amoebae that expressed human CD46 or CD55 were protected from lysis by mouse serum, indicating that display of human proteins was sufficient to inhibit mouse complement activation. Finally, amoebae were allowed to perform trogocytosis of a cell type in which the complement pathway is not conserved, and they did not become resistant to lysis. Overall, these findings are consistent with the model that trogocytosis enables amoebic acquisition and display of host proteins, including negative regulators of the complement pathway, that provide protection from complement lysis. Since other microbes can perform trogocytosis, this novel mechanism for complement resistance might apply to other infections.
- Open Access
- 26 April 2022
- Published by American Society for Microbiology in mBio
- Vol. 13 (2) , e0316321
Entamoeba histolytica Develops Resistance to Complement Deposition and Lysis after Acquisition of Human Complement-Regulatory Proteins through Trogocytosis
Entamoeba histolyticais the cause of amoebiasis, a diarrheal disease of global importance. While infection is often asymptomatic, the trophozoite (amoeba) form of this parasite is capable of invading and ulcerating the intestine and can disseminate through the bloodstream to other organs.
- 26 April 2022
- Published by American Society for Microbiology in mBio
- Vol. 13 (2) , e0316321
Open AccessEntamoeba histolytica Develops Resistance to Complement Deposition and Lysis after Acquisition of Human Complement-Regulatory Proteins through Trogocytosis
Entamoeba histolyticais the cause of amoebiasis, a diarrheal disease of global importance. While infection is often asymptomatic, the trophozoite (amoeba) form of this parasite is capable of invading and ulcerating the intestine and can disseminate through the bloodstream to other organs.
- 27 January 2022
- Published by Wiley in Current Protocols
- Vol. 2 (1) , e327
Growth and Genetic Manipulation of Entamoeba histolytica
Entamoeba histolytica is a parasitic protozoan and the causative agent of amoebiasis in humans. Amoebiasis has a high incidence of disease, resulting in ∼67,900 deaths per year, and it poses a tremendous burden of morbidity and mortality in children. Despite its importance, E. histolytica is an understudied parasite. These protocols describe the in vitro growth, maintenance, cryopreservation, genetic manipulation, and cloning of axenic E. histolytica trophozoites. There has been significant progress in genetic manipulation of this organism over the past decade, and these protocols outline the ways in which these advances can be implemented. © 2022 Wiley Periodicals LLC.Basic Protocol 1: Culturing E. histolytica trophozoitesSupport Protocol 1: Preparation of TYI‐S‐33 mediumSupport Protocol 2: Lot testing of Biosate peptone and adult bovine serum for TYI‐S‐33 mediumBasic Protocol 2: Cryopreservation of E. histolytica trophozoitesSupport Protocol 3: Preparation of cryoprotectant solutionsBasic Protocol 3: Transfection of E. histolytica trophozoites with Attractene reagentBasic Protocol 4: Creating clonal lines using limiting dilutionBasic Protocol 5: Knockdown of one to two genes with trigger‐induced RNA interferenceSupport Protocol 4: Evaluation of RNA interference knockdown with reverse transcriptase PCRBasic Protocol 6: E. histolytica growth curves
- 27 January 2022
- Published by Wiley in Current Protocols
- Vol. 2 (1) , e327
Growth and Genetic Manipulation of Entamoeba histolytica
Entamoeba histolytica is a parasitic protozoan and the causative agent of amoebiasis in humans. Amoebiasis has a high incidence of disease, resulting in ∼67,900 deaths per year, and it poses a tremendous burden of morbidity and mortality in children. Despite its importance, E. histolytica is an understudied parasite. These protocols describe the in vitro growth, maintenance, cryopreservation, genetic manipulation, and cloning of axenic E. histolytica trophozoites. There has been significant progress in genetic manipulation of this organism over the past decade, and these protocols outline the ways in which these advances can be implemented. © 2022 Wiley Periodicals LLC.Basic Protocol 1: Culturing E. histolytica trophozoitesSupport Protocol 1: Preparation of TYI‐S‐33 mediumSupport Protocol 2: Lot testing of Biosate peptone and adult bovine serum for TYI‐S‐33 mediumBasic Protocol 2: Cryopreservation of E. histolytica trophozoitesSupport Protocol 3: Preparation of cryoprotectant solutionsBasic Protocol 3: Transfection of E. histolytica trophozoites with Attractene reagentBasic Protocol 4: Creating clonal lines using limiting dilutionBasic Protocol 5: Knockdown of one to two genes with trigger‐induced RNA interferenceSupport Protocol 4: Evaluation of RNA interference knockdown with reverse transcriptase PCRBasic Protocol 6: E. histolytica growth curves
- Open Access
- 29 November 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (11) , e1010088
Establishment of quantitative RNAi-based forward genetics in Entamoeba histolytica and identification of genes required for growth
While Entamoeba histolytica remains a globally important pathogen, it is dramatically understudied. The tractability of E. histolytica has historically been limited, which is largely due to challenging features of its genome. To enable forward genetics, we constructed and validated the first genome-wide E. histolytica RNAi knockdown mutant library. This library allows for Illumina deep sequencing analysis for quantitative identification of mutants that are enriched or depleted after selection. We developed a novel analysis pipeline to precisely define and quantify gene fragments. We used the library to perform the first RNAi screen in E. histolytica and identified slow growth (SG) mutants. Among genes targeted in SG mutants, many had annotated functions consistent with roles in cellular growth or metabolic pathways. Some targeted genes were annotated as hypothetical or lacked annotated domains, supporting the power of forward genetics in uncovering functional information that cannot be gleaned from databases. While the localization of neither of the proteins targeted in SG1 nor SG2 mutants could be predicted by sequence analysis, we showed experimentally that SG1 localized to the cytoplasm and cell surface, while SG2 localized to the cytoplasm. Overexpression of SG1 led to increased growth, while expression of a truncation mutant did not lead to increased growth, and thus aided in defining functional domains in this protein. Finally, in addition to establishing forward genetics, we uncovered new details of the unusual E. histolytica RNAi pathway. These studies dramatically improve the tractability of E. histolytica and open up the possibility of applying genetics to improve understanding of this important pathogen.
- 29 November 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (11) , e1010088
Open AccessEstablishment of quantitative RNAi-based forward genetics in Entamoeba histolytica and identification of genes required for growth
While Entamoeba histolytica remains a globally important pathogen, it is dramatically understudied. The tractability of E. histolytica has historically been limited, which is largely due to challenging features of its genome. To enable forward genetics, we constructed and validated the first genome-wide E. histolytica RNAi knockdown mutant library. This library allows for Illumina deep sequencing analysis for quantitative identification of mutants that are enriched or depleted after selection. We developed a novel analysis pipeline to precisely define and quantify gene fragments. We used the library to perform the first RNAi screen in E. histolytica and identified slow growth (SG) mutants. Among genes targeted in SG mutants, many had annotated functions consistent with roles in cellular growth or metabolic pathways. Some targeted genes were annotated as hypothetical or lacked annotated domains, supporting the power of forward genetics in uncovering functional information that cannot be gleaned from databases. While the localization of neither of the proteins targeted in SG1 nor SG2 mutants could be predicted by sequence analysis, we showed experimentally that SG1 localized to the cytoplasm and cell surface, while SG2 localized to the cytoplasm. Overexpression of SG1 led to increased growth, while expression of a truncation mutant did not lead to increased growth, and thus aided in defining functional domains in this protein. Finally, in addition to establishing forward genetics, we uncovered new details of the unusual E. histolytica RNAi pathway. These studies dramatically improve the tractability of E. histolytica and open up the possibility of applying genetics to improve understanding of this important pathogen.